NO994390L - Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors - Google Patents
Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitorsInfo
- Publication number
- NO994390L NO994390L NO994390A NO994390A NO994390L NO 994390 L NO994390 L NO 994390L NO 994390 A NO994390 A NO 994390A NO 994390 A NO994390 A NO 994390A NO 994390 L NO994390 L NO 994390L
- Authority
- NO
- Norway
- Prior art keywords
- benzothepines
- hmg
- combination therapy
- bile acid
- reductase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4066097P | 1997-03-11 | 1997-03-11 | |
PCT/US1998/003792 WO1998040375A2 (en) | 1997-03-11 | 1998-03-10 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO994390D0 NO994390D0 (en) | 1999-09-10 |
NO994390L true NO994390L (en) | 1999-11-04 |
Family
ID=21912237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO994390A NO994390L (en) | 1997-03-11 | 1999-09-10 | Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0971744A2 (en) |
JP (1) | JP2002500628A (en) |
CN (1) | CN1255864A (en) |
AU (1) | AU730024C (en) |
BG (1) | BG103793A (en) |
BR (1) | BR9808013A (en) |
CA (1) | CA2283575A1 (en) |
HU (1) | HUP0002395A3 (en) |
IL (1) | IL131872A0 (en) |
MX (1) | MXPA99008417A (en) |
NO (1) | NO994390L (en) |
NZ (1) | NZ337830A (en) |
PL (1) | PL336415A1 (en) |
RU (1) | RU2247579C2 (en) |
SK (1) | SK125099A3 (en) |
WO (1) | WO1998040375A2 (en) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6083497A (en) | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
AU2003241629B2 (en) * | 1999-04-19 | 2005-06-16 | Astrazeneca Ab | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
SE0000772D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
WO2001068096A2 (en) * | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
SE0003766D0 (en) * | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002051396A1 (en) * | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Pharmaceutical compositions containing cyclobutene derivatives |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
BRPI0212346B1 (en) | 2001-09-08 | 2016-02-02 | Albireo Ab | COMPOUNDS DERIVED FROM BENZOTIADIAZEPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF WITH INHIBITING EFFECTS ON THE TRANSPORTATION OF ILEAL BILE ACID, PROCESS FOR THE PREPARATION OF THE SAME, USE THEREOF, AND, PHARMACEUTICAL COMPOSITION. |
WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
MXPA04005864A (en) | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases. |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
KR100990524B1 (en) * | 2002-08-28 | 2010-10-29 | 아사히 가세이 파마 가부시키가이샤 | Novel quaternary ammonium compounds |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
US7973030B2 (en) | 2004-02-27 | 2011-07-05 | Asahi Kasei Pharma Corporation | Benzothiazepine and benzothiepine compounds |
ES2552657T3 (en) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibitors of the recycling of bile acids and satiogens for the treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
EP3400944B1 (en) | 2010-11-08 | 2020-07-15 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
WO2012064267A1 (en) | 2010-11-08 | 2012-05-18 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
EP2770990A4 (en) | 2011-10-28 | 2015-03-11 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
SG10201407013QA (en) | 2011-10-28 | 2014-12-30 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
CN105228615A (en) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | Be used for the treatment of the bile acid recycling inhibitors of Barrett esophagus and gastroesophageal reflux disease |
MX2015013193A (en) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease. |
JO3301B1 (en) | 2013-04-26 | 2018-09-16 | Albireo Ab | Crystal modifications of elobixibat |
US10709755B2 (en) | 2014-06-25 | 2020-07-14 | Elobix Ab | Solid formulation and method for preventing or reducing coloration thereof |
WO2016045642A1 (en) | 2014-09-28 | 2016-03-31 | National Institute Of Biological Sciences, Beijing | Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
EP3413878B1 (en) | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
EP3413877B1 (en) | 2016-02-09 | 2021-04-07 | Albireo AB | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3664782A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20210024033A (en) | 2018-06-20 | 2021-03-04 | 알비레오 에이비 | Pharmaceutical formulation of odebiccibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
ES2955799T3 (en) | 2019-02-06 | 2023-12-07 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
HRP20230039T1 (en) | 2019-02-06 | 2023-06-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
CN114072152A (en) | 2019-02-12 | 2022-02-18 | 米鲁姆制药公司 | Genotype and dose-dependent response to ASBTI in patients with bile salt efflux pump deficiency |
ES2973355T3 (en) | 2019-12-04 | 2024-06-19 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
AR120682A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS |
WO2021110883A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202134220A (en) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
AR120674A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID |
EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
TW202134222A (en) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | Benzothia(di)azepine compounds and their use as bile acid modulators |
FI4069360T3 (en) | 2019-12-04 | 2024-02-20 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023537285A (en) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
CN112274648B (en) * | 2020-11-23 | 2022-10-14 | 郑州大学 | Preparation method of cholesterol oxidase modified hybrid metal organic framework tumor targeting nano preparation |
EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
US20240140922A1 (en) * | 2022-08-22 | 2024-05-02 | Enanta Pharmaceuticals, Inc. | Fused heterobicyclic antiviral agents |
-
1998
- 1998-03-10 JP JP53959498A patent/JP2002500628A/en not_active Abandoned
- 1998-03-10 SK SK1250-99A patent/SK125099A3/en unknown
- 1998-03-10 MX MXPA99008417A patent/MXPA99008417A/en unknown
- 1998-03-10 NZ NZ337830A patent/NZ337830A/en not_active Application Discontinuation
- 1998-03-10 CA CA002283575A patent/CA2283575A1/en not_active Abandoned
- 1998-03-10 CN CN98804995A patent/CN1255864A/en active Pending
- 1998-03-10 IL IL13187298A patent/IL131872A0/en unknown
- 1998-03-10 BR BR9808013-0A patent/BR9808013A/en not_active IP Right Cessation
- 1998-03-10 PL PL98336415A patent/PL336415A1/en unknown
- 1998-03-10 WO PCT/US1998/003792 patent/WO1998040375A2/en not_active Application Discontinuation
- 1998-03-10 RU RU99121514/15A patent/RU2247579C2/en not_active IP Right Cessation
- 1998-03-10 EP EP98910075A patent/EP0971744A2/en not_active Withdrawn
- 1998-03-10 AU AU64408/98A patent/AU730024C/en not_active Ceased
- 1998-03-10 HU HU0002395A patent/HUP0002395A3/en unknown
-
1999
- 1999-09-10 NO NO994390A patent/NO994390L/en not_active Application Discontinuation
- 1999-10-11 BG BG103793A patent/BG103793A/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL336415A1 (en) | 2000-06-19 |
JP2002500628A (en) | 2002-01-08 |
NO994390D0 (en) | 1999-09-10 |
AU730024C (en) | 2004-08-05 |
MXPA99008417A (en) | 2005-02-03 |
AU6440898A (en) | 1998-09-29 |
RU2247579C2 (en) | 2005-03-10 |
SK125099A3 (en) | 2001-02-12 |
CA2283575A1 (en) | 1998-09-17 |
EP0971744A2 (en) | 2000-01-19 |
NZ337830A (en) | 2001-07-27 |
HUP0002395A2 (en) | 2001-05-28 |
BG103793A (en) | 2000-07-31 |
BR9808013A (en) | 2001-09-25 |
HUP0002395A3 (en) | 2002-12-28 |
WO1998040375A2 (en) | 1998-09-17 |
WO1998040375A3 (en) | 1998-12-03 |
IL131872A0 (en) | 2001-03-19 |
AU730024B2 (en) | 2001-02-22 |
CN1255864A (en) | 2000-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO994390D0 (en) | Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors | |
DK1216247T3 (en) | Imidazoimidazoles and triazoles as anti-inflammatory agents | |
NO20010016L (en) | Benzothiepines with activity as inhibitors of ileal bile acid transport and uptake of taurocholate | |
ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
NO990296D0 (en) | The HPPD gene and inhibitors | |
MXPA03003417A (en) | Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor. | |
NO20001323D0 (en) | Dipeptide-apoptosis inhibitors and their use | |
DK0944590T3 (en) | Aminoguanidines and alkoxyguanidines as protease inhibitors | |
GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
NO993956L (en) | Goal tracking procedure | |
IL135428A0 (en) | Ace inhibitor-mmp inhibitor combinations | |
DK0914124T3 (en) | Antithrombotic, antiatherosclerotic, pharmaceutical composition comprising a thienopyridine derivative and an HMG-CoA reductase inhibitor | |
AU6760798A (en) | Bax inhibitor proteins | |
AU9802798A (en) | Gas treating solution corrosion inhibitor | |
NO20000682D0 (en) | Gasket and dispenser | |
AU9197598A (en) | Inducing neurotransmitter and neuropeptide activity | |
AU8673598A (en) | Neuraminidase inhibitors | |
NO20000371L (en) | Aminoethylphenoxyacetic acid derivatives and drugs for pain reduction and limestone removal in urinary lithiasis | |
DK1032559T3 (en) | Aminoalkylphenol derivatives for the treatment of depression and memory failure | |
EP1232159A4 (en) | Beta-amyloid peptide inhibitors | |
AU3721000A (en) | Corrosion inhibitor and process | |
AU8968598A (en) | Bovine footrot treatment and prevention | |
HUP0201597A3 (en) | Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines | |
DK199901135A (en) | Procedure and arrangement for carrying out financial transactions | |
NO303034B1 (en) | Receipt note for cash register and the like |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |